These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 27385523)

  • 21. How to introduce a rotigotine patch to Parkinson's disease patients taking oral dopamine agonists.
    Yasutaka Y; Fujioka S; Mishima T; Shibaguchi H; Tsuboi Y; Kamimura H
    Clin Neurol Neurosurg; 2020 Dec; 199():106266. PubMed ID: 33059317
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rotigotine transdermal patch in Chinese patients with early Parkinson's disease: A randomized, double-blind, placebo-controlled pivotal study.
    Zhang ZX; Shang HF; Hu X; Chen S; Zhao Z; Du X; Surmann E; Bauer L; Asgharnejad M
    Parkinsonism Relat Disord; 2016 Jul; 28():49-55. PubMed ID: 27172830
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug safety evaluation of rotigotine.
    Sprenger FS; Seppi K; Poewe W
    Expert Opin Drug Saf; 2012 May; 11(3):503-12. PubMed ID: 22468676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An observational study of rotigotine transdermal patch and other currently prescribed therapies in patients with Parkinson's disease.
    Müller T; Tolosa E; Badea L; Asgharnejad M; Grieger F; Markowitz M; Nondonfaz X; Bauer L; Timmermann L
    J Neural Transm (Vienna); 2018 Jun; 125(6):953-963. PubMed ID: 29484495
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rotigotine for nocturnal hypokinesia in Parkinson's disease: Quantitative analysis of efficacy from a randomized, placebo-controlled trial using an axial inertial sensor.
    Bhidayasiri R; Sringean J; Chaiwong S; Anan C; Penkeaw N; Leaknok A; Boonpang K; Saksornchai K; Rattanachaisit W; Thanawattano C; Jagota P
    Parkinsonism Relat Disord; 2017 Nov; 44():124-128. PubMed ID: 28818560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics, safety, and tolerability of rotigotine transdermal system in healthy Japanese and Caucasian subjects following multiple-dose administration.
    Cawello W; Kim SR; Braun M; Elshoff JP; Masahiro T; Ikeda J; Funaki T
    Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):353-62. PubMed ID: 25773763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics, safety and tolerability of rotigotine transdermal patch in healthy Japanese and Caucasian subjects.
    Cawello W; Kim SR; Braun M; Elshoff JP; Ikeda J; Funaki T
    Clin Drug Investig; 2014 Feb; 34(2):95-105. PubMed ID: 24178238
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rotigotine transdermal delivery for the treatment of Parkinson's disease.
    Rascol O; Perez-Lloret S
    Expert Opin Pharmacother; 2009 Mar; 10(4):677-91. PubMed ID: 19239399
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of rotigotine transdermal patch in patients with Parkinson's disease presenting with non-motor symptoms - results of a double-blind, randomized, placebo-controlled trial.
    Antonini A; Bauer L; Dohin E; Oertel WH; Rascol O; Reichmann H; Schmid M; Singh P; Tolosa E; Chaudhuri KR
    Eur J Neurol; 2015 Oct; 22(10):1400-7. PubMed ID: 26095948
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study.
    LeWitt PA; Lyons KE; Pahwa R;
    Neurology; 2007 Apr; 68(16):1262-7. PubMed ID: 17438216
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical studies with transdermal rotigotine in early Parkinson's disease.
    Poewe W; Luessi F
    Neurology; 2005 Jul; 65(2 Suppl 1):S11-4. PubMed ID: 16030290
    [No Abstract]   [Full Text] [Related]  

  • 32. Rotigotine: the first new chemical entity for transdermal drug delivery.
    McAfee DA; Hadgraft J; Lane ME
    Eur J Pharm Biopharm; 2014 Nov; 88(3):586-93. PubMed ID: 25173087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rotigotine: a novel dopamine agonist for the transdermal treatment of Parkinson's disease.
    Zareba G
    Drugs Today (Barc); 2006 Jan; 42(1):21-8. PubMed ID: 16511608
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rotigotine transdermal patch in the management of Parkinson's disease (PD) and its night-time use for PD-related sleep disorders.
    Antonini A; Bernardi L; Calandrella D; Mancini F; Plebani M
    Funct Neurol; 2010; 25(1):21-5. PubMed ID: 20626993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rotigotine transdermal patch enables rapid titration to effective doses in advanced-stage idiopathic Parkinson disease: subanalysis of a parallel group, open-label, dose-escalation study.
    Babic T; Boothmann B; Polivka J; Rektor I; Boroojerdi B; Häck HJ; Randerath O
    Clin Neuropharmacol; 2006; 29(4):238-42. PubMed ID: 16855426
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Continued Use of Rotigotine Transdermal Patches for Parkinson Disease].
    Yasutaka Y; Fujioka S; Shibaguchi H; Imakyure O; Washiyama A; Tsuboi Y; Futagami K
    Brain Nerve; 2016 Jun; 68(6):655-60. PubMed ID: 27279164
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rotigotine transdermal patch in Chinese patients with advanced Parkinson's disease: A randomized, double-blind, placebo-controlled pivotal study.
    Zhang ZX; Liu CF; Tao EX; Shao M; Liu YM; Wang J; Asgharnejad M; Xue HB; Surmann E; Bauer L
    Parkinsonism Relat Disord; 2017 Nov; 44():6-12. PubMed ID: 28827011
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-ergot dopamine agonist rotigotine as a promising therapeutic tool in atypical parkinsonism syndromes: a 24 months pilot observational open-label study.
    Moretti DV; Binetti G; Zanetti O; Frisoni GB
    Neuropharmacology; 2014 Oct; 85():284-9. PubMed ID: 24915072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease.
    Güldenpfennig WM; Poole KH; Sommerville KW; Boroojerdi B
    Clin Neuropharmacol; 2005; 28(3):106-10. PubMed ID: 15965307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K; Lyons KE
    Pharmacotherapy; 2009 Dec; 29(12):1452-67. PubMed ID: 19947805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.